Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 4.92%.

  • Corcept Therapeutics' EBITDA Margin fell 206100.0% to 4.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.85%, marking a year-over-year decrease of 139600.0%. This contributed to the annual value of 20.29% for FY2024, which is 19500.0% down from last year.
  • Latest data reveals that Corcept Therapeutics reported EBITDA Margin of 4.92% as of Q3 2025, which was down 206100.0% from 13.72% recorded in Q2 2025.
  • Corcept Therapeutics' 5-year EBITDA Margin high stood at 32.09% for Q4 2021, and its period low was 2.17% during Q1 2025.
  • Its 5-year average for EBITDA Margin is 22.03%, with a median of 23.39% in 2023.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 68500bps in 2021, then tumbled by -206100bps in 2025.
  • Corcept Therapeutics' EBITDA Margin (Quarter) stood at 32.09% in 2021, then plummeted by -32bps to 21.83% in 2022, then grew by 7bps to 23.39% in 2023, then tumbled by -41bps to 13.89% in 2024, then plummeted by -65bps to 4.92% in 2025.
  • Its EBITDA Margin stands at 4.92% for Q3 2025, versus 13.72% for Q2 2025 and 2.17% for Q1 2025.